Royalty Pharma plc (RPRX) – Company Press Releases
-
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
-
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
-
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
-
Royalty Pharma to Present at Upcoming Investor Conferences
-
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
-
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
-
Royalty Pharma Reports Second Quarter 2023 Results
-
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
-
Royalty Pharma Declares Third Quarter 2023 Dividend
-
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Royalty Pharma Reports First Quarter 2023 Results
-
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
-
Royalty Pharma Declares Second Quarter 2023 Dividend
-
Royalty Pharma Declares Second Quarter 2023 Dividend
-
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
-
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
-
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
-
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
-
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
-
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
-
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
-
Royalty Pharma Raises Full Year 2023 Guidance
-
Royalty Pharma Raises Full Year 2023 Guidance
-
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
-
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
-
Royalty Pharma Reports Q4 and Full Year 2022 Results
-
Royalty Pharma Reports Q4 and Full Year 2022 Results
-
Royalty Pharma to Present at Upcoming Investor Conferences
-
Royalty Pharma to Present at Upcoming Investor Conferences
-
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
-
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
-
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
-
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
-
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
-
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
-
Royalty Pharma Announces Dividend Increase
-
Royalty Pharma Announces Dividend Increase
-
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
-
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
-
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
-
Royalty Pharma Announces Expansion of Senior Leadership Team
-
Royalty Pharma Announces Expansion of Senior Leadership Team
-
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
-
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
-
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
-
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
-
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
-
Royalty Pharma Reports Third Quarter 2022 Results
-
Royalty Pharma Reports Third Quarter 2022 Results
Back to RPRX Stock Lookup
